Role of SGLT-2 Inhibitors in Ultrafiltration Failure in Peritoneal Dialysis: A Narrative Review
Canadian Journal of Kidney Health and Disease · 2024-12 · 11
DOI: 10.1177/20543581241293500 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Canadian Journal of Kidney Health and Disease, online erschienen am 05.11.2024. Verfasst von Magdalena Riedl Khursigara und 3 weiteren Autor:innen. Beteiligte Einrichtung: Broad Institute of MIT and Harvard, Cambridge, MA, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Krescent.
Abstract (Originalsprache)
Purpose of review: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are glucose lowering agents with protective effects on cardiovascular health and the ability to slow chronic kidney disease (CKD) progression. The benefits of SGLT-2 inhibitors have not been studied in patients with advanced CKD or on maintenance dialysis. Ultrafiltration failure is a common reason for failure of peritoneal dialysis (PD). Glucose transporters, such as SGLT-2, are involved in the progression to ultrafiltration failure, and hence, SGLT-2 inhibitors might be beneficial in patients on PD to prevent ultrafiltration failure. Source of information: Here, we review data from animal models and ongoing clinical trials of SGLT-2 inhibitors in advanced CKD, as well as considerations for a phase III trial in patients on PD. Methods: A literature search was conducted and information on clinical trials was obtained from clinicaltrials.gov. Key findings: Animal models of PD have shown upregulation of glucose transporters in the peritoneal membrane and a potential effect of SGLT-2 inhibitors on glucose absorption and ultrafiltration. Several clinical trials are currently ongoing with SGLT-2 inhibitors in patients on PD. We discuss their study designs and propose a mixed-methods, patient-centered approach to studying SGLT-2 inhibitors in PD patients. We also discuss the potential implications of SGLT-2 inhibitors on people living with kidney failure, especially in remote communities.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, AB, Canada.
- Providence Research, Vancouver, BC, Canada.
- Division of Nephrology, Department of Medicine, Research Institute, McGill University Health Center, Montreal, QC, Canada.
ORCID-Profile: Magdalena Riedl Khursigara
Förderung
- Krescent
Zitieren
APA
Riedl Khursigara, M., Liu, P., Kaur, R., & Mavrakanas, T. A. (2024). Role of SGLT-2 Inhibitors in Ultrafiltration Failure in Peritoneal Dialysis: A Narrative Review. Canadian Journal of Kidney Health and Disease, 11. https://doi.org/10.1177/20543581241293500
Vancouver
Riedl Khursigara M, Liu P, Kaur R, Mavrakanas TA. Role of SGLT-2 Inhibitors in Ultrafiltration Failure in Peritoneal Dialysis: A Narrative Review. Canadian Journal of Kidney Health and Disease. 2024;11. doi:10.1177/20543581241293500
BibTeX
@article{RiedlKhursigara2024,
author = {Riedl Khursigara, Magdalena and Liu, Ping and Kaur, Reetinder and Mavrakanas, Thomas A},
title = {Role of SGLT-2 Inhibitors in Ultrafiltration Failure in Peritoneal Dialysis: A Narrative Review},
journal = {Canadian Journal of Kidney Health and Disease},
year = {2024},
volume = {11},
doi = {10.1177/20543581241293500}
}
EUVIMED